Australian study backs first-line use of rituximab for NMOSD

An Australian study provides additional support for the use of the B-cell depleting therapy rituximab as a first line treatment of neuromyelitis optica spectrum disorder (NMOSD). The retrospective, unblinded observational study comprised 75 patients who met the International Panel for NMO Diagnosis (IPND) criteria for NMOSD. Of these, 68 were AQP4 antibody positive and complete ...

Already a member?

Login to keep reading.

© 2022 the limbic